Search Results - Therapeutics

49 Results Sort By:
Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.
Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...
Published: 2/8/2024   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier
Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Drug Delivery, Therapeutics
TREM2 Monoclonal Antibody for Therapeutic and Diagnostic Use
Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. Previous studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. UTHealth inventors created and...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Therapeutics, Oncology, Diagnostics
EGFL6 Specific Monoclonal Antibodies for Cancer Diagnostic and Therapeutic Use
Human epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) was discovered in tumors and fetal tissues. Upregulated expression of EGFL6 was found in a variety of cancer cell types, such as ovarian cancer and lung cancer. Unlike VEGF, which was expressed in ovarian cancer tissues and in healing wounds, EGFL6 was expressed mainly in tumor-associated...
Published: 12/19/2023   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Biologics, Therapeutics
Identifying and characterizing genes whose perturbation leads to intracranial aneurysms (IA) and/or vascular endothelial cell dysfunction
The proposed invention involves identification and characterization of molecular targets for treating intracranial aneurysms. A focus is endothelial podosomes regulated by the transmembrane receptor protein THSD1. THSD1 also regulates autophagy processes that contribute to aneurysm formation as well as positively regulates TGFβ signaling, which...
Published: 8/15/2023   |   Inventor(s):  
Keywords(s):  
Category(s): Neurology/Neurosurgery, Therapeutics, Diagnostics
Synthetic Antifungal Peptides
­Novel antifungal compositions that inhibit fungal growth which have both medical and non-medical utility and applications Inventors at the University of Texas Health Science Center at Houston have developed a series of novel peptide compounds to inhibit fungal growth. The peptides are based on the bacteriocin EntV, which is secreted by Enterococcus...
Published: 2/8/2024   |   Inventor(s): Danielle Garsin, Michael Lorenz
Keywords(s):  
Category(s): Biologics, Therapeutics
LGR4 Specific Monoclonal Antibodies and Their Use
­Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...
Published: 8/15/2023   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials
Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy
­R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...
Published: 8/15/2023   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment
­ Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...
Published: 8/15/2023   |   Inventor(s): Balveen Kaur, BangXing Hong
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Co-Administration of Oncolytic Herpes Simplex Virus (oHSV) with Cisplatin for Anti-Cancer Immunotherapy
­Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel...
Published: 8/15/2023   |   Inventor(s): Balveen Kaur
Keywords(s):  
Category(s): Therapeutics, Oncology
1 2 3 4 5 
© 2024. All Rights Reserved. Powered by Inteum